GSK 356278

Drug Profile

GSK 356278

Alternative Names: GSK356278

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Huntington's disease; Major depressive disorder

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in Netherlands (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in United Kingdom (PO)
  • 15 Mar 2012 No development reported - Phase-I for Anxiety disorders in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top